The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
This study was a single-arm, exploratory clinical study. Patients with advanced pancreatic cancer were screened and enrolled according to the inclusion and exclusion criteria described in the study protocol. Informed consent was signed after full communication. Patients with advanced pancreatic cancer who received first-line treatment were treated with Trilaciclib +mFOLFIRINOX. The incidence of chemotherapy-induced myelosuppression was used as the primary endpoint to observe whether Trilaciclib could reduce the occurrence or degree of chemotherapy-induced myelosuppression.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-75 years
ECOG score 0 or 1
Expected survival≥12 weeks
Patients with histologically or cytologically confirmed pancreatic cancer
Have not received any antineoplastic therapy prior to treatment
Major organ functions within 7 days prior to treatment shall meet the following criteria: a. Neutrophil count ≥1.5×109 /L； b. Hemoglobin ≥10g/dL； c. Platelet count ≥100×109 /L
Biochemical examination shall meet the following standards: a、Total bilirubin(TBIL)≤1.5times the upper limit of normal value(ULN); b、ALT and AST≤1.5×ULN ; c、creatinine clearance(CCr)≥60ml/min
Patients of reproductive age(including female and male patients'female companions)must use effective birth control measures
Subjects voluntarily joined the study and signed an informed consent form(ICF)
It is expected that the patient has good compliance and can follow up the efficacy and adverse reactions according to the protocol requirements
You may not be if
Had received systemic antineoplastic therapy
Pregnant and lactating women. Women of childbearing age had to test a negative pregnancy test within 7 days before enrollment
Substance abuse, clinical or psychological or social factors that may interfere with informed consent or the conduct of the study
